Scarica l'app Stockscreener
28.99
2.80%
0.79
Dopo l'orario di chiusura:
29.00
0.01
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.20
Aprire:
$28.38
Volume 24 ore:
1.60M
Relative Volume:
0.66
Capitalizzazione di mercato:
$4.79B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
14.87
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
-0.92%
1M Prestazione:
-2.72%
6M Prestazione:
-1.23%
1 anno Prestazione:
-1.26%
Intervallo 1D:
$28.19
$29.06
Intervallo di 1 settimana:
$27.89
$29.27
Portata 52W:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Confronta ALKS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
28.99 | 4.66B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
127.89 | 54.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.50 | 44.92B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.06B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.99 | 28.42B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
485.77 | 20.55B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Alkermes (Nasdaq: ALKS) to Join Evercore, Piper Sandler Healthcare Investor Conferences - Stock Titan
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
United StatesGoodwin Advises Avadel Pharmaceuticals On Increased Offer From Alkermes - Mondaq
How Analysts See the Alkermes Story Changing After Acquisition Moves and New Narcolepsy Data - Yahoo Finance
Is Alkermes plc (8AK) stock a fit for income portfoliosRecession Risk & Consistent Growth Stock Picks - newser.com
Alkermes stock rating reiterated at Neutral by H.C. Wainwright - Investing.com Australia
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal - Finviz
Will Alkermes plc (8AK) stock benefit from mergersWeekly Investment Recap & Community Supported Trade Ideas - newser.com
Is Alkermes plc (8AK) stock good for wealth creation2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Is Alkermes plc (8AK) stock among top earnings playsEarnings Risk Summary & Free Weekly Watchlist of Top Performers - newser.com
What momentum indicators show for Alkermes plc stockWeekly Trade Review & Accurate Intraday Trade Tips - newser.com
Will Alkermes plc (8AK) stock benefit from infrastructure billMarket Movers & Growth Focused Stock Pick Reports - newser.com
Applying Elliott Wave Theory to Alkermes plcWeekly Risk Report & Daily Chart Pattern Signals - newser.com
What recovery options are there for Alkermes plcMarket Trend Report & Reliable Entry Point Alerts - newser.com
Alkermes Fires Back In Bidding War With Lundbeck Over Avadel - Citeline News & Insights
Alkermes, Avadel Bump Deal To $2.37B After Alternate Bid - Law360
Avadel Pharmaceuticals agrees to sweetened $2.37B takeover bid from Alkermes amid bidding war - The Business Journals
Alkermes increases offer for Avadel to $21 in cash plus CVR - Investing.com Nigeria
What data driven models say about Alkermes plc’s futureChart Signals & Proven Capital Preservation Tips - newser.com
Risk vs reward if holding onto Alkermes plcQuarterly Portfolio Review & Reliable Volume Spike Trade Alerts - newser.com
ALKS: NT2 study data support flexible orexin dosing, robust safety, and strategic market expansion - TradingView
Alkermes prevails over Lundbeck in Avadel bidding war - Pharmaceutical Technology
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri - Finviz
Avadel board backs Alkermes' higher offer over Lundbeck proposal - Reuters
Avadel Pharmaceuticals Agrees to Alkermes’ Revised Acquisition Offer - PharmExec.com
Alkermes Faces Bidding Battle For Avadel Pharmaceuticals - Finimize
Alkermes Faces Pressure to Secure the Buyout of Avadel After Lundbeck's Unsolicited Bid, RBC Says - MarketScreener
Alkermes escalates bidding war; US biotech risks ‘falling behind’ China - BioPharma Dive
Alkermes Ups Bid for Avadel to $2.37 Billion After Rival Offer - Contract Pharma
H Lundbeck A/S says noted that our offer for acquiring Avadel no longer is considered superior by their board, we are currently considering our options - MarketScreener
Alkermes (ALKS) Increases Buyout Offer for Avadel Pharmaceuticals (AVDL) - GuruFocus
Alkermes raises offer for Avadel acquisition and secures $1.5 billion loan facility - Investing.com Australia
How high can Alkermes plc stock goWeekly Stock Report & Weekly Setup with High ROI Potential - newser.com
Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN
Why Alkermes plc stock is a must watch in 2025July 2025 Analyst Calls & Real-Time Stock Price Movement Reports - newser.com
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alkermes Plc Azioni (ALKS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Nov 03 '25 |
Sale |
30.38 |
9,000 |
273,442 |
69,740 |
1.83%
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):